Home

Hepion Pharmaceuticals, Inc. - Common Stock (HEPA)

0.4100
-0.0300 (-6.82%)
NASDAQ · Last Trade: Apr 9th, 3:06 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment
Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently
Via Spotlight Growth · May 22, 2023